How to Titrate Ryzodeg (Insulin Degludec/Insulin Aspart)
Start Ryzodeg at 10 units once daily with your largest meal, then increase by 2 units every 3 days based on fasting glucose until you reach target without hypoglycemia. 1
Initial Dosing
- Starting dose: 10 units once daily OR 0.1-0.2 units/kg per day 1
- Timing: Administer with the largest or most carbohydrate-rich meal of the day 2
- Alternative approach: If switching from basal insulin, can start unit-for-unit at same total daily dose 2
Titration Algorithm
The evidence-based approach follows these steps:
- Set your fasting plasma glucose (FPG) target based on individualized glycemic goals 1
- Increase dose by 2 units every 3 days to reach FPG goal 1
- Titrate weekly in 2-unit steps when adjusting based on patient response 2
- Monitor for hypoglycemia: If it occurs without clear cause, reduce dose by 10-20% 1
Intensification to Twice-Daily Dosing
When once-daily dosing fails to achieve A1C targets:
- Add second injection with breakfast and main evening meal 3
- Redistribute total daily dose: Split between the two meals 2
- Continue titration: Adjust each dose independently based on pre-meal glucose readings 2
- Target: Pre-meal plasma glucose of 4.0-5.0 mmol/L 3
Key Monitoring Points
Assess insulin adequacy at every visit by looking for:
- Overbasalization signals: Elevated bedtime-to-morning glucose differential, postprandial-to-preprandial differential 1
- Hypoglycemia: Both aware and unaware episodes 1
- High glucose variability 1
Special Considerations
When adding other medications:
- Sulfonylureas: Frequently need discontinuation or dose reduction 2
- SGLT2 inhibitors or GLP-1 RAs: May require Ryzodeg dose reduction when added 2
Common pitfall: The 2025 ADA guidelines 1 provide general basal insulin titration guidance, but Ryzodeg contains both basal (degludec) and prandial (aspart) components. The prandial component means you must time doses with meals, unlike pure basal insulins that can be given at any consistent time.
Practical advantage: Ryzodeg demonstrated superior fasting glucose control and lower hypoglycemia rates compared to biphasic insulin aspart 30, with lower total daily insulin requirements 3. This makes aggressive titration safer than with older premixed insulins.